We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Agilent Technologies Acquires Diagnostic and Research Product Developer

By Labmedica staff writers
Posted on 23 May 2007
Agilent Technologies, Inc. (Palo Alto, CA, USA) announced that it has signed a definitive agreement with Stratagene Corp. (La Jolla, CA, USA) to acquire the developer, manufacturer, and marketer of diagnostic and specialized life-science research products. The acquisition is expected to close in approximately 90 days, subject to certain closing conditions.

Stratagene's products are used by scientists in academia, government research, and industry, in molecular biology, genomics, proteomics, drug discovery, and toxicology. Stratagene's portfolio includes reagents for life-science research and instruments. The company offers a range of diagnostics products, including applications for allergy testing and urinalysis.

We see Stratagene's technology, products, and expertise as being highly complementary to Agilent's life sciences portfolio, enabling us to offer our customers more complete workflow solutions, said Nick Roelofs, vice president and general manager of Agilent's Life Sciences Solutions Unit.

Stratagene has a strong R&D team as well as excellent presence in the important academic and government markets, Mr. Roelofs added.


Related Links:
Agilent
Stratagene Corp

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
23 May 2007  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
23 May 2007  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
23 May 2007  |   Industry



PURITAN MEDICAL